MRGPRX2 and skin infection: Given that HDPs including protegrin-1 activate human MCs via MRGPRX2 (22, 23, 29), raises the interesting possibility that potential therapeutic action of murepavadin for P. aeruginosa skin infection likely reflects both MRGPRX2-mediated MC activation and its direct antimicrobial activity.